Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea.
Sooam Biotech Research Foundation, 64 Kyungin-ro, Guro-gu, Seoul, 08359, Republic of Korea.
BMC Biotechnol. 2019 Jan 3;19(1):1. doi: 10.1186/s12896-018-0491-5.
Genetic engineering technology such as clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system provides a powerful tool for developing disease models and determining gene functions. Recent interests in canine cancer models have highlighted the necessity of developing genetic engineering tools for dogs. In this study, we attempted to generate optimized CRISPR/Cas9 system to target canine tumor protein 53 (TP53), one of the most crucial tumor suppressor genes, to establish TP53 knockout canine cells for canine cancer research.
We constructed CRISPR/Cas9 vectors using each of three TP53 gene-targeting guide RNAs (gRNAs) with minimal off-target potential. After transfection, we obtained several clones of TP53 knockout cells containing "indel" mutations in the targeted locus which had infinite cellular life span, resistance to genotoxicity, and unstable genomic status in contrast to normal cells. Of the established TP53 knockout cells, TP53KO#30 cells targeted by TP53 gRNA #30 showed non-cancerous phenotypes without oncogenic activation both in vitro and in vivo. More importantly, no off-target alteration was detected in TP53KO#30 cells. We also tested the developmental capacity of TP53 knockout cells after application of the somatic cell nuclear transfer technique.
Our results indicated that TP53 in canine cells was effectively and specifically targeted by our CRISPR/Cas9 system. Thus, we suggest our CRISPR/Cas9-derived canine TP53 knockout cells as a useful platform to reveal novel oncogenic functions and effects of developing anti-cancer therapeutics.
基因编辑技术如成簇规律间隔短回文重复(CRISPR)/Cas9 系统为开发疾病模型和确定基因功能提供了强大的工具。最近对犬科癌症模型的兴趣突显了开发犬科遗传工程工具的必要性。在这项研究中,我们试图生成优化的 CRISPR/Cas9 系统来靶向犬科肿瘤蛋白 53(TP53),这是最重要的肿瘤抑制基因之一,以建立用于犬科癌症研究的 TP53 敲除犬科细胞。
我们使用三种具有最小脱靶潜力的 TP53 基因靶向 guide RNA(gRNA)构建了 CRISPR/Cas9 载体。转染后,我们获得了几个 TP53 敲除细胞克隆,这些克隆在靶向基因座中含有“indel”突变,具有无限的细胞寿命、对遗传毒性的抗性和不稳定的基因组状态,与正常细胞相反。在所建立的 TP53 敲除细胞中,靶向 TP53 gRNA #30 的 TP53KO#30 细胞在体外和体内均表现出非癌表型,没有致癌激活。更重要的是,在 TP53KO#30 细胞中未检测到脱靶改变。我们还测试了应用体细胞核转移技术后 TP53 敲除细胞的发育能力。
我们的结果表明,我们的 CRISPR/Cas9 系统有效地靶向了犬科细胞中的 TP53。因此,我们建议使用我们的 CRISPR/Cas9 衍生的犬科 TP53 敲除细胞作为揭示新的致癌功能和开发抗癌治疗方法的有用平台。